Items where authors include "Craig, Z"

Article

McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370

Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029

Platt, JR, Williams, CJM orcid.org/0000-0002-1574-653X, Craig, Z et al. (4 more authors) (2023) Personalising Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer: Protocols for the International Phase III FOxTROT2 and FOxTROT3 Randomised-Controlled Trials. Colorectal Disease. ISSN 1462-8910

Allsup, DJ, Craig, Z orcid.org/0000-0001-9930-6648, Cairns, D orcid.org/0000-0002-2338-0179 et al. (13 more authors) (2022) Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. American Journal of Hematology, 97 (5). E168-E171. ISSN 0361-8609

Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048

Bradbury, CA, Craig, Z orcid.org/0000-0001-9930-6648, Cook, G orcid.org/0000-0003-0223-3652 et al. (14 more authors) (2020) Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. Blood. ISSN 0006-4971

Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Proceedings Paper

McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .